ResearchGeneral gynecologyThe economic burden of noncervical human papillomavirus disease in the United States
Section snippets
Materials and Methods
We focused on 7 HPV-related conditions: HPV-6– and -11–associated anogenital warts, HPV-6– and -11–associated JORRP, and HPV-16– and -18–associated noncervical genital cancers (including anus, penis, vagina, vulva) and cancers of the mouth and oropharynx.
Juvenile-onset Recurrent Respiratory Papillomatosis
Cost estimates for juvenile-onset recurrent respiratory papillomatosis were obtained from a published study.9 In this study, the discounted lifetime cost per case was estimated at $131,910, with a wide plausible range of $54,800-$276,170. Base case assumptions included an average duration of illness of 4.2 years during which each patient underwent 4.4 surgical procedures per year, a ratio of follow-up office visits to surgery of 3:1, and a tracheotomy rate of 11%.9 Costs that were considered
Comment
Despite formidable data gaps, our review of secondary data and estimation of the direct medical costs that are associated with 7 HPV-related conditions demonstrate a substantial economic burden imposed by HPV-attributable noncervical disease in the United States. With the use of an incidence-based approach, the economic burden associated with noncervical HPV-related conditions that occurred in the United States in the year 2003 approximates $418 million. This figure has a considerably wide
References (41)
- et al.
Chapter 2: the burden of HPV-related cancers
Vaccine
(2006) - et al.
Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease
Vaccine
(2006) - et al.
Chapter 13: current findings from prophylactic HPV vaccine trials
Vaccine
(2006) - et al.
Review of the economic and quality-of-life burden of cervical human papillomavirus disease
Am J Obstet Gynecol
(2007) - et al.
The costs of head and neck oncology: primary tumours, recurrent tumours and long-term follow-up
Eur J Cancer
(2001) - et al.
Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis
Am J Pathol
(2001) - et al.
Heterogeneous etiology of squamous carcinoma of the vulva
Obstet Gynecol
(1996) - et al.
Human papillomavirus in squamous cell carcinoma of the vulva by polymerase chain reaction
Obstet Gynecol
(1997) - et al.
A population-based study of squamous cell vaginal cancer: HPV and cofactors
Gynecol Oncol
(2002) - et al.
Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men
Am J Med
(2000)
Cost analysis of neonatal circumcision in a large health maintenance organization
J Urol
Carcinoma of the vulva: FIGO 6th annual report on the results of treatment in gynecological cancer
Int J Gynaecol Obstet
Prevention of genital HPV infection and sequelae: report of an external consultants' meeting: Department of Health and Human Services
Human papillomavirus: the burden of infection
Obstet Gynecol Surv
The estimated direct medical cost of sexually transmitted diseases among American youth, 2000
Perspect Sex Reprod Health
Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature
Pharmacoeconomics
The cost of juvenile-onset recurrent respiratory papillomatosis
Arch Otolaryngol Head Neck Surg
The health and economic burden of genital warts in a set of private health plans in the United States
Clin Infect Dis
Direct medical costs for surgical and medical treatment of condylomata acuminata
Arch Dermatol
The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts
Am J Manag Care
Cited by (139)
Hemoptysis and Bronchiolitis Obliterans in Children with Recurrent Respiratory Papillomatosis: Adverse Reactions to Nebulized Cidofovir
2019, Archivos de BronconeumologiaMean treatment cost of incident cases of penile cancer for privately insured patients in the United States
2019, Urologic Oncology: Seminars and Original InvestigationsMean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas
2018, Gynecologic OncologyCitation Excerpt :Depending on the stage at detection and other factors, vaginal cancer may be treated with surgery, radiation therapy, and/or chemotherapy. Healthcare cost estimates for vulvar and vaginal cancers used in leading HPV economic models, including that in a 2010 study by Elbasha and Dasbach, were taken from research by Hu and Goldie [11]. However, those cost estimates were derived from a survey of the literature and scenario analyses because of the lack of empirical studies on the lifetime costs of these cancers.
Disparities in HPV and the HPV Vaccine Knowledge Among Non-Hispanic Black Adults in the US - HINTS 2017–2020
2024, Journal of Immigrant and Minority Health
This study was supported in part by grant 1406-04-07-CT-66327 from the Centers for Disease Control and Prevention and R01 CA093435 from the National Cancer Institute.
Cite this article as: Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008;198:500.e1-500.e7.